Best Myeloma doctors in Germany: TOP 6 doctors

• Dr. Elke Jaeger specializes in Myeloma treatment with 35+ years of experience.
• Utilizes stem cell transplantation, chemotherapy, and targeted therapy for Myeloma.
• Recognized as a top sarcoma specialist, also adept in Myeloma care.
• Head physician at a leading Oncology and Hematology Center in Germany.
• Ranked among the best German oncologists by the Focus rating.
• Provides online consultations for patients with Myeloma.
• Fluent in both German and English, ensuring clear communication.

• Dr. Eckhart Weidemann specializes in advanced Myeloma treatment.
• Utilizes chemotherapy, stem cell transplant, and targeted therapy for Myeloma.
• International practice in Germany and research collaborations worldwide.
• Holds vital hematology certifications, ensuring expert care.
• Member of esteemed hematology and oncology societies.
• Offers online consultations for Myeloma patients globally.
• Fluent in German and English, facilitating diverse patient communication.

Dr. Viola Fox is the Chief Physician at the Clinic for Haematology, Oncology, and Palliative Medicine at BKZ Solingen. This clinic is a certified interdisciplinary cancer center. Dr. Fox is a leading expert in drug therapy for tumor diseases in Germany and Europe. She has more than 15 years of experience in this field.

She is a member of the German Society of Oncology and Haemato-oncology (GDHO), the German Association of Physicians, and the American Association for Cancer Research. Dr. Fox is also active in molecular biology research. Her work supports progress in cancer treatment and molecular diagnostics.

Her main areas of expertise are chemotherapy, immunotherapy, targeted therapy, and radiation therapy. Dr. Fox is known for her innovative methods and strong commitment to patient care. Her efforts have led to high recovery rates and recognition from her peers.

She completed her training at the Charité in Berlin and has been a specialist in radiotherapy for 20 years. She worked as a senior physician in all departments of the Charité in Berlin, and from 2007 to 2015 she was a senior physician and deputy director of the Charité clinic in Berlin. In 2015, she was appointed head of the department of radiotherapy at the University Hospital of Cologne and very successfully headed the clinic there until 2022. Since the end of 2022, she has been heading the private radiotherapy clinic "RadioOnkologie Vosspalais". Clinical areas include radioimmunotherapy, high-precision therapy, multimodal therapy of gynecological tumors and prostate carcinoma.

Professor Dr. Marnitz is a member of the German and European Guidelines for the Therapy of Endometrial Carcinoma. She is also an independent external expert of the European Council for the Therapy of Carcinoma of the Cervical, Vulvar and Vaginal Cancer. Professor Dr. Marnitz is a member of the German and European Guidelines for the Therapy of Endometrial Carcinoma. She is also an independent external expert of the European Council for the Therapy of Carcinoma of the Cervical, Vulvar and Vaginal Cancer. Several randomized clinical trials have been conducted under her leadership.

Professor Dr. Marnitz is an honorary member of the Russian Society of Gynecological Oncology, a member of the professional societies DEGRO, ESTRO, ASTRO. In 2024, Professor Dr. Marnitz will be the president of the congress of the annual conference of the German Society of Radiation Oncology.

• Dr. Bernd Hertenstein focuses on Myeloma treatment with 32 years of experience.
• Expert in chemotherapy, stem cell transplantation, and precision-targeted therapy.
• Utilizes treatment approaches: immunotherapy, bisphosphonates, and radiation therapy.
• International practice in countries such as Germany, USA, and Switzerland.
• Holds accreditation for his expertise in Clinical Oncology.
• Member of various prestigious oncological societies, ensuring updated practices.
• Consults patients online, offering convenience for Myeloma sufferers.
• Fluent in German and English, facilitating clear communication with patients.